SU1480761A3 - Способ получени добутамина тартрата или добутамина лактобионата - Google Patents
Способ получени добутамина тартрата или добутамина лактобионата Download PDFInfo
- Publication number
- SU1480761A3 SU1480761A3 SU853995134A SU3995134A SU1480761A3 SU 1480761 A3 SU1480761 A3 SU 1480761A3 SU 853995134 A SU853995134 A SU 853995134A SU 3995134 A SU3995134 A SU 3995134A SU 1480761 A3 SU1480761 A3 SU 1480761A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- dobutamine
- tartrate
- lactobionate
- hydrochloride
- water
- Prior art date
Links
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229960001089 dobutamine Drugs 0.000 title claims abstract description 28
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 8
- 229940099584 lactobionate Drugs 0.000 title abstract description 3
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 title abstract description 3
- 229940095064 tartrate Drugs 0.000 title description 2
- 229960001654 dobutamine hydrochloride Drugs 0.000 claims abstract description 14
- WZIUXGZIVZDXIG-WUUYCOTASA-N (2s,3s)-2,3-dihydroxybutanedioic acid;4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 WZIUXGZIVZDXIG-WUUYCOTASA-N 0.000 claims abstract description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 5
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940099563 lactobionic acid Drugs 0.000 claims abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 9
- XSGHHWMGNIMZCA-FPOQQNBBSA-N 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoic acid Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1.OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O XSGHHWMGNIMZCA-FPOQQNBBSA-N 0.000 claims description 6
- 210000000748 cardiovascular system Anatomy 0.000 claims description 4
- 101150025129 POP1 gene Proteins 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 238000002360 preparation method Methods 0.000 abstract description 6
- 206010019280 Heart failures Diseases 0.000 abstract description 3
- 238000006386 neutralization reaction Methods 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 5
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulphite Substances [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- -1 (+) - dobutamine tartrate salts Chemical class 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000005792 cardiovascular activity Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AEELXMHQIJJMKP-DMTCNVIQSA-N (2r,3s)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@@H](S)CO AEELXMHQIJJMKP-DMTCNVIQSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 101100061447 Caenorhabditis elegans crn-6 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/10—Polyhydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/10—Polyhydroxy carboxylic acids
- C07C59/105—Polyhydroxy carboxylic acids having five or more carbon atoms, e.g. aldonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Seasonings (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68440484A | 1984-12-20 | 1984-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1480761A3 true SU1480761A3 (ru) | 1989-05-15 |
Family
ID=24747892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU853995134A SU1480761A3 (ru) | 1984-12-20 | 1985-12-18 | Способ получени добутамина тартрата или добутамина лактобионата |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0187019B1 (OSRAM) |
| JP (1) | JPS61155355A (OSRAM) |
| KR (1) | KR870000803B1 (OSRAM) |
| CN (1) | CN1009922B (OSRAM) |
| AT (1) | ATE58370T1 (OSRAM) |
| AU (1) | AU589929B2 (OSRAM) |
| CA (1) | CA1254909A (OSRAM) |
| CS (1) | CS253734B2 (OSRAM) |
| DD (1) | DD241071A5 (OSRAM) |
| DE (2) | DE3580575D1 (OSRAM) |
| DK (1) | DK589385A (OSRAM) |
| EG (1) | EG17889A (OSRAM) |
| ES (2) | ES8705841A1 (OSRAM) |
| FI (1) | FI855018A7 (OSRAM) |
| GR (1) | GR853027B (OSRAM) |
| HU (1) | HU194805B (OSRAM) |
| MY (1) | MY104814A (OSRAM) |
| NZ (1) | NZ214583A (OSRAM) |
| PH (1) | PH22547A (OSRAM) |
| PL (1) | PL148296B1 (OSRAM) |
| PT (1) | PT81705B (OSRAM) |
| RO (1) | RO93391B (OSRAM) |
| SU (1) | SU1480761A3 (OSRAM) |
| ZA (1) | ZA859629B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA881076B (en) * | 1987-02-24 | 1989-10-25 | Lilly Co Eli | Dobutamine salts |
| FR2740337B1 (fr) * | 1995-10-27 | 1997-11-21 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees contenant un derive ayant une activite adrenergique |
| FR2740338B1 (fr) * | 1995-12-01 | 1997-12-05 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees contenant de la dobutamine |
| FR2809619B1 (fr) * | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
| CN105906515B (zh) * | 2015-12-10 | 2018-03-13 | 菏泽市方明制药有限公司 | 一种盐酸多巴酚丁胺脱色工艺 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987200A (en) * | 1972-04-12 | 1976-10-19 | Eli Lilly And Company | Method for increasing cardiac contractility |
| FR2333499A1 (fr) * | 1975-12-01 | 1977-07-01 | Roussel Uclaf | Nouveau derive de la phenethylamine et ses sels, procede de preparation et application a titre de medicament |
-
1985
- 1985-12-16 RO RO121165A patent/RO93391B/ro unknown
- 1985-12-17 GR GR853027A patent/GR853027B/el unknown
- 1985-12-17 FI FI855018A patent/FI855018A7/fi not_active Application Discontinuation
- 1985-12-17 NZ NZ214583A patent/NZ214583A/xx unknown
- 1985-12-17 PL PL1985256848A patent/PL148296B1/pl unknown
- 1985-12-17 ZA ZA859629A patent/ZA859629B/xx unknown
- 1985-12-18 PT PT81705A patent/PT81705B/pt not_active IP Right Cessation
- 1985-12-18 SU SU853995134A patent/SU1480761A3/ru active
- 1985-12-18 DE DE8585309216T patent/DE3580575D1/de not_active Expired - Lifetime
- 1985-12-18 CA CA000497954A patent/CA1254909A/en not_active Expired
- 1985-12-18 KR KR1019850009534A patent/KR870000803B1/ko not_active Expired
- 1985-12-18 PH PH33213A patent/PH22547A/en unknown
- 1985-12-18 CS CS859449A patent/CS253734B2/cs unknown
- 1985-12-18 DE DE198585309216T patent/DE187019T1/de active Pending
- 1985-12-18 DD DD85284649A patent/DD241071A5/de not_active IP Right Cessation
- 1985-12-18 AT AT85309216T patent/ATE58370T1/de not_active IP Right Cessation
- 1985-12-18 EP EP85309216A patent/EP0187019B1/en not_active Expired - Lifetime
- 1985-12-18 DK DK589385A patent/DK589385A/da not_active Application Discontinuation
- 1985-12-18 EG EG809/85A patent/EG17889A/xx active
- 1985-12-18 AU AU51415/85A patent/AU589929B2/en not_active Ceased
- 1985-12-19 JP JP60287570A patent/JPS61155355A/ja active Granted
- 1985-12-19 ES ES550151A patent/ES8705841A1/es not_active Expired
- 1985-12-19 CN CN85109229A patent/CN1009922B/zh not_active Expired
- 1985-12-19 HU HU854878A patent/HU194805B/hu not_active IP Right Cessation
-
1987
- 1987-02-26 ES ES557426A patent/ES8802570A1/es not_active Expired
- 1987-10-08 MY MYPI87002873A patent/MY104814A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Патент US № 3987200, кл. кл,424-330, опублик, 1976. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1272989A3 (ru) | Способ получени диазабицикло (3,3,1) нонанов | |
| Peck et al. | Streptomyces antibiotics. IX. Dihydrostreptomycin | |
| US3993639A (en) | Heptaminol adenosine-5'-monophosphate | |
| US4698361A (en) | Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same | |
| KR870000803B1 (ko) | 도부타민 염의 제조방법 | |
| DE1809119C3 (de) | Infarktprophylaktikum | |
| US2601204A (en) | Process of lowering blood prothrombin level and lengthening clotting time with methylenebis-hydroxy coumarin | |
| NO137636B (no) | Fremgangsm}te for behandling av avl¦psvann | |
| Hanzlik et al. | Blood and symptomatic changes following the intravenous administration of a variety of agents and solutions | |
| AU2023319214A1 (en) | Pharmaceutical composition containing pyrrole gastric acid secretion inhibitor and preparation method therefor | |
| DE2743704C2 (de) | L- oder DL-Phenylglycine enthaltende Arzneimittel | |
| EP0280461A2 (en) | Dobutamine salts | |
| SU1766910A1 (ru) | Литиева соль N- @ -изобутоксибензоил- @ -аминомасл ной кислоты, обладающа активностью улучшать микроциркул цию мозга | |
| KR860000450B1 (ko) | α-6-데옥씨-5-하이드록씨 테트라 싸이클린과 소듐 테트라메타포스 페이트의 수용성 복합체의 제조방법 | |
| DE3878494T2 (de) | Mittel gegen zuckerkrankheit. | |
| SU621148A1 (ru) | Вещество, антикоагул нтную активность | |
| CN101732331B (zh) | 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物 | |
| US4088759A (en) | Injectable pharmaceutical solutions | |
| SU591474A1 (ru) | -Арилсульфониламины бензо-(в)тиофен-1,1-диоксидов,обладающих спазмолитической и холинолитической активностью | |
| US3812099A (en) | Polymer derivative of 1-methyl-5/5-oxo-4-ethyl-tetrahydrofuryl-(3)-methyl/imidazole with cellulose glycolic acid | |
| US2275623A (en) | Medicinal preparation | |
| SU822829A1 (ru) | Симпатолитическое средство | |
| JPS59508B2 (ja) | ノウケツカンカクチヨウザイ ２ ３− チカン −４− フクソカンジヨウアミノスルホニルベンゼンスルホンアミド ノ セイホウ | |
| KR810000112B1 (ko) | 신규의 알루미늄 화합물의 제조방법 | |
| KR800000449B1 (ko) | 벤젠설포닐-우레아의 제조방법 |